San Diego-based Mirati Therapeutics Inc. said Jan. 6 that it priced its public offering at $5.60 per share, raising up to $65 million before underwriting and related expenses. The offering is expected to close Jan. 11.
The clinical-stage biotechnology firm is working on medicines for targeted oncology. The company said it plans to use the net proceeds for clinical development of its three product candidates, glesatinib, sitravatinib and mocetinostat, as well as for development of preclinical programs and working capital.
Boston-based investment bank Leerink Partners LLC, which specializes in healthcare, is acting as sole book-runner for the offering.
